[Skip to Content]
[Skip to Content Landing]
Views 667
Citations 0
Letters
February 6, 2013

β-Blocker Use for Patients With or at Risk for Coronary Artery Disease

Author Affiliations
 

Letters Section Editor: Jody W. Zylke, MD, Senior Editor.

Author Affiliation: Department of Medicine, Baylor College of Medicine, Houston, Texas (cshang9@gmail.com).

JAMA. 2013;309(5):438. doi:10.1001/jama.2012.128869

To the Editor: It is unfortunate that the observational study on β-blocker use and clinical outcomes in stable outpatients did not distinguish different types of β-blockers.1 In a review of β-blockers for hypertension, three-quarters of participants in randomized controlled trials (RCTs) used atenolol.2 Atenolol has been shown repeatedly to be no better than placebo in improving clinical outcomes such as reduction of mortality and cardiovascular events in RCTs and meta-analyses.2,3

First Page Preview View Large
First page PDF preview
First page PDF preview
×